

Supplementary Table. Continued

Year	Study design	Author	Eligible patients	Aetiology of ED ^a	Age (y)	Duration of ED (y)	Shocks per treatment	Total shock	EFD (mL/mm ²)	IIEF-5			EHS				
										Baseline	3 mo	6 mo	12 mo	Baseline	3 mo	6 mo	12 mo
2020	Prospective study	Huang et al. [34]	35	4	33 (21–68)	n/a	5,000	20,000	0.09	10.60±5.99	n/a	n/a	n/a	3 (1–3)	n/a	n/a	n/a
2020	RCT	Kim et al. [35]	38	4	63.2±5.4	n/a	3,000	36,000	n/a	n/a	n/a	n/a	n/a	2.5±0.9	n/a	n/a	n/a
2020	Comparative study	Verze et al. [36]	78	3	56.0±9.6	n/a	n/a	n/a	0.09	15.5±2.8	n/a	n/a	n/a	n/a	n/a	n/a	n/a
			26 ^b				1,500	9,000		15.2	18.9	18.5					
			26 ^b				1,800	10,800		16.4	20.6	19.8					
			26 ^b				2,400	14,400		14.9	19.9	19.6					
2020	Retrospective study	Wang et al. [37]	45	4	n/a	n/a	10,000	80,000	0.05	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
			7 ^b		60 (30–81)	2.75 (1–5)				16 (16–18)	21 (20–23)						
2020	RCT	Sramkova et al. [38]	38 ^b	1	61 (30–84)	3.58 (0.5–10)	6,000	24,000	0.16	12.8±3.9	20.8 (19.3–22.3)	n/a	n/a	2.1±0.5	3.6 (3.3–3.8)	n/a	n/a
2020	Comparative study	Eryilmaz et al. [39]	40	1	n/a	n/a	1,800	21,600	0.15	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
			20 ^b		44.3					10.01±2.5				2.01±0.95			
			20 ^b		45.6					9.6±2.9				2.1±0.73			
2020	RCT	Beccagli et al. [40]	36	2	64.6±5.3	n/a	2,400	19,200	0.09	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
2021	Prospective study	Akande et al. [42]	22	1	53.73±8.013	n/a	1,500	18,000	n/a	8.27±2.741	n/a	n/a	n/a	n/a	n/a	n/a	n/a
2021	RCT	Ladegaard et al. [43]	20	2	60.8±6.8	n/a	4,000	20,000	0.15	6.80±3.04	n/a	n/a	n/a	1.30±0.73	n/a	n/a	n/a
2021	Prospective study	Lau et al. [44]	19	4	57.4 (38–70)	3.86 (1–10)	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
			16 ^b							13.1±5.7				2.44±1.03			
			17 ^b							12.7±5.7	17.2±6.5			2.41±1.00	2.82±0.95		
			11 ^b							11.6±6.0				2.18±1.08			
2021	RCT	Shendy et al. [45]	21	3	48.6±5.5	9.8±1.1	3,000	36,000	0.09	12.75±3.21	n/a	n/a	n/a	n/a	n/a	n/a	n/a
2021	Retrospective study	Tzou et al. [46]	69	4	55 (45–66)	1 (0.5–3)	3,000	36,000	0.2	10.5±5.54	n/a	n/a	n/a	2±0.80	n/a	n/a	n/a
2021	Comparative study	Lei et al. [47]	46	4	33.4±6.2	2 (1–3)	1,500	18,000	0.09	14.09±3.75	21.52 (18.90–24.14)	n/a	n/a	1.96±0.73	3.04 (2.77–3.31)	n/a	n/a
2021	Retrospective study	Geyik [48]	93	4	51.23±11.36	3.97±2.97	3,600	18,000	0.09	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
2021	Retrospective study	Garetta et al. [49]	111	1	53.7±11.6	n/a	2,400	14,400	0.12	12.2±6.9	16.7±8.4	15.9±8.2	n/a	n/a	n/a	n/a	n/a
2021	Prospective study	Palmeri et al. [50]	106	1	57.9±10.7	2.78±2.35	3,000	18,000	0.25	n/a	n/a	n/a	n/a	2.19±0.52	n/a	n/a	n/a
2021	RCT	Vinay et al. [41]	40	1	60 (54–66)	3 (2–6)	5,000	20,000	0.09	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
2021	Prospective study	Kanalose et al. [51]	34	2	59.2±6.8	n/a	1,500	18,000	0.09	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
2021	RCT	Ortaç et al. [52]	44	1	42.32±9.88	2.8±3.0	3,000	12,000	0.20	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
2022	Prospective study	Daneshwar et al. [53]	50	4	41.9±11.7	n/a	3,000	30,000	0.25	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
2022	Retrospective study	Geyik [54]	41	4	51.61±11.80	4.54±2.75	3,600	36,000	0.09	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
2022	Prospective study	Ogniski et al. [55]	50	4	59 (51–70)	4 (2–7)	3,000	18,000	0.22	13 (8.75–17.25)	17 (12–22)	13.5 (10–17.25)	n/a	1 (0–2)	2 (1–3)	2 (1–2)	n/a
2022	RCT	Gallo et al. [56]	83	4	n/a	n/a	3,000	18,000	0.25	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
			41 ^b		50.5±13.7									2.07±0.72			3.17±0.67
			42 ^b		49.6±14.0									2.12±0.80			2.95±0.76
2022	Retrospective study	Ghahani et al. [57]	94	4	56.6 (±10.74)	n/a	n/a	n/a	n/a	12.71±5.27	n/a	n/a	n/a	2.01±0.94	n/a	n/a	n/a
			20 ^b				3,000	24,000	0.09	9.50±5.05				1.55±1.07			
			20 ^b				10,000	80,000	n/a	14.00±5.15				2.05±0.86			
			31 ^b				3,000	24,000	0.09	12.10±3.86				2.10±0.59			
			23 ^b				10,000	80,000	n/a	15.43±5.56				2.29±1.12			

Supplementary Table. Continued

Year	Study design	Author	Eligible patients	Aetiology of ED ^a	Age (y)	Duration of ED (y)	Shocks per treatment	Total shock	EFD (mJ/mm ²)	IIEF-5			EHS			
										Baseline	3 mo	6 mo	12 mo	Baseline	3 mo	6 mo
2022	RCT	Kalyvanakis et al. [58]	35	1	54 (47–63)	5.67 (2.92–10.35)	5,000	60,000	0.09	n/a	n/a	n/a	n/a	n/a	n/a	n/a
2022	RCT	Sandoval-Salinas et al. [59]	40	4	47.4±12.8	5.5±6.6	6,000	36,000	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
2022	RCT	Tao et al. [61]	33	3	46.70±4.93	3.66±2.26	2,100	25,200	n/a	n/a	n/a	n/a	1.85±0.36	n/a	n/a	n/a
2022	Prospective study	Cocci et al. [62]	5	5	31 (24–26)	n/a	3,000	24,000	0.25	10 (8–13)	21 (19–23)	n/a	n/a	n/a	n/a	n/a
2022	Prospective study	Ergün et al. [63]	63	3	57.11±5.06	2.10±0.46	5,000	60,000	0.15	5.29±1.67	5.56±1.85	n/a	1.46±0.50	1.48±0.50	n/a	n/a
2023	RCT	Chung et al. [60]	30	1	45 (42–58)	2.75 (0.67–4.92)	3,000	36,000	0.25	14.6±3.8	18.8±3.8	18.8±3.8	1.4±0.6	2.6±0.5	2.6±0.4	n/a

ED, erectile dysfunction; EFD, energy flux density; IIEF-5, International Index of Erectile Function-5; EHS, Erection Hardness Score; n/a, not available; RCT, randomized controlled trial.

^a1, vasculogenic/organic; 2, postprostatectomy; 3, non defined/mixed.^bThe data of the subgroups separately analysed in the studies.